Brazilian company launches obesity pen with domestic production

g1.globo.com (Portuguese)

A Brazilian pharmaceutical company will launch an obesity treatment pen in August, marking the first 100% Brazilian-made product in the global GLP-1 analog market. The medication, named Olire, contains liraglutide. The company, EMS, received approval in December and plans to produce 200,000 pens this year, with over 500,000 units available in Brazil within a year. They will also launch Lirux, a pen for type 2 diabetes, and plan to release a semaglutide pen in 2026. Olire and Lirux will be priced 10-20% below market references. These medications, administered daily via injection, work by reducing appetite.


With a significance score of 3.2, this news ranks in the top 10% of today's 30649 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Brazilian company launches obesity pen with domestic production | News Minimalist